F Bach1, F J Uddin, D Burke. 1. Department of Academic Surgery, Room B40, Clarendon Wing, Leeds General Infirmary, Great George Street, Leeds, West Yorkshire LS1 3EX, UK.
Abstract
BACKGROUND: Tumour growth is dependant upon the development of an adequate blood supply. This, in turn, is thought to depend upon a switch by the tumour, from a dormant to angiogenic state. Recent data suggest that this switch may occur when the balance of pro- and anti-angiogenic agents alters to promote angiogenesis. Angiopoietins may be involved in this balance. METHODS: An electronic literature search was performed with respect to angiopoietins from 1996 to the present. Published data from in-vitro and in-vivo studies were critically analysed. A specific focus was made of studies relating to tumour growth and vasculature. RESULTS: Since angiopoietin-1 was first described in 1996, three more angiopoietins have been described. All family members bind to the Tie-2 receptor. There is now a considerable accumulation of data that suggests they play a pivotal role in the development and stabilisation of tumour vasculature. angiopoietin-2 appears to be pro-angiogenic whilst angiopoietin-1 appears to be a stabilising factor. CONCLUSIONS: Recent trials of anti-angiogenic agents show promise in the treatment of solid human cancers. The angiopoietins are a new family of proteins that appear to be influential in the development of the tumour vasculature. Manipulation of the angiopoietin balance may provide a potential therapeutic target in human cancer.
BACKGROUND:Tumour growth is dependant upon the development of an adequate blood supply. This, in turn, is thought to depend upon a switch by the tumour, from a dormant to angiogenic state. Recent data suggest that this switch may occur when the balance of pro- and anti-angiogenic agents alters to promote angiogenesis. Angiopoietins may be involved in this balance. METHODS: An electronic literature search was performed with respect to angiopoietins from 1996 to the present. Published data from in-vitro and in-vivo studies were critically analysed. A specific focus was made of studies relating to tumour growth and vasculature. RESULTS: Since angiopoietin-1 was first described in 1996, three more angiopoietins have been described. All family members bind to the Tie-2 receptor. There is now a considerable accumulation of data that suggests they play a pivotal role in the development and stabilisation of tumour vasculature. angiopoietin-2 appears to be pro-angiogenic whilst angiopoietin-1 appears to be a stabilising factor. CONCLUSIONS: Recent trials of anti-angiogenic agents show promise in the treatment of solid humancancers. The angiopoietins are a new family of proteins that appear to be influential in the development of the tumour vasculature. Manipulation of the angiopoietin balance may provide a potential therapeutic target in humancancer.
Authors: Ana P D Demasi; Carolina A B Silva; Alessandra D Silva; Cristiane Furuse; Andresa B Soares; Albina Altemani; Marcelo H Napimoga; Vera C Araújo Journal: Head Neck Pathol Date: 2011-09-25
Authors: Johanna C Bendell; Tamara Sauri; Antonio Cubillo Gracián; Rafael Alvarez; Carlos López-López; Pilar García-Alfonso; Maen Hussein; Maria-Luisa Limon Miron; Andrés Cervantes; Clara Montagut; Cristina Santos Vivas; Alberto Bessudo; Patricia Plezia; Veerle Moons; Johannes Andel; Jaafar Bennouna; Andre van der Westhuizen; Leslie Samuel; Simona Rossomanno; Christophe Boetsch; Angelika Lahr; Izolda Franjkovic; Florian Heil; Katharina Lechner; Oliver Krieter; Herbert Hurwitz Journal: Oncologist Date: 2019-09-30